Medication for contrast allergy is an important consideration for anyone undergoing imaging procedures such as CT or MRI scans that require contrast media. Iodinated and gadolinium-based contrast agents can trigger reactions ranging from mild urticaria to life-threatening anaphylaxis, making appropriate pharmacological management essential. Pre-medication with corticosteroids and antihistamines is used to reduce the risk of repeat reactions in high-risk patients, whilst adrenaline remains the cornerstone of emergency treatment. This article explains how contrast reactions occur, which medications are used to prevent and treat them, and what patients and clinicians need to know about NHS protocols and individual risk factors.

What Is a Contrast Allergy and How Does It Occur?

Contrast reactions range from mild urticaria to anaphylaxis and may involve IgE-mediated or non-IgE-mediated mechanisms; severe reactions to modern non-ionic low-osmolar agents occur in fewer than 1 in 10,000 administrations.

Contrast media — also referred to as contrast agents or dyes — are substances administered during imaging procedures such as CT scans, MRI scans, and angiography to enhance the visibility of internal structures. Iodinated contrast media are the most commonly used type, particularly in CT and fluoroscopic imaging, whilst gadolinium-based agents are used in MRI. Although generally well tolerated, a proportion of patients experience adverse reactions, ranging from mild discomfort to severe, life-threatening responses. Severe immediate reactions to modern non-ionic, low-osmolar iodinated contrast agents are rare, occurring in fewer than 1 in 10,000 administrations. Immediate hypersensitivity reactions to gadolinium-based contrast agents are uncommon but can occur.

Experiencing these side effects? Our pharmacists can help you navigate them →

Contrast reactions are broadly classified into two categories:

• Immediate reactions — occurring within one hour of administration, these include urticaria (hives), bronchospasm, angioedema, and anaphylaxis.

• Delayed reactions — occurring between one hour and one week after exposure, typically presenting as skin rashes or flu-like symptoms.

The precise mechanism underlying contrast reactions is not fully understood. Immediate reactions were historically attributed to histamine release triggered by the osmolarity of older ionic contrast agents. Modern non-ionic, low-osmolar contrast media have significantly reduced this risk, yet reactions still occur. Current evidence suggests that some reactions involve immunological pathways — including IgE-mediated hypersensitivity — whilst others are non-IgE-mediated (non-allergic) immediate hypersensitivity reactions, involving direct mast cell activation without prior sensitisation. This distinction is clinically important because it influences how future exposures are managed.

It is worth noting that the term 'contrast allergy' is commonly used by patients and clinicians alike, though not all reactions represent true allergic responses in the immunological sense. Regardless of the underlying mechanism, any prior reaction to contrast media should be documented clearly in the patient's medical records and communicated to the imaging team before any subsequent procedure.

Relevant guidance: ESUR Guidelines on Contrast Agents (latest version); Royal College of Radiologists (RCR) standards on intravascular contrast agent administration.

Medications Used to Prevent and Treat Contrast Reactions

Corticosteroids and antihistamines are used for pre-medication, whilst intramuscular adrenaline is the first-line emergency treatment for anaphylaxis; antihistamines treat cutaneous symptoms only and must not delay adrenaline.

The pharmacological management of contrast reactions falls into two distinct categories: pre-medication given prophylactically before the procedure, and emergency treatment administered in response to an acute reaction. Understanding the role of each drug class is essential for both clinicians and patients.

Corticosteroids are the cornerstone of pre-medication protocols. Agents such as prednisolone (oral) or hydrocortisone (intravenous) work by suppressing the inflammatory cascade, reducing the release of mediators such as histamine, leukotrienes, and prostaglandins. Their mechanism involves binding to intracellular glucocorticoid receptors, ultimately inhibiting the transcription of pro-inflammatory cytokines. Because corticosteroids require several hours to exert their full effect, they must be administered well in advance of contrast exposure — typically at 12 hours and again at 2 hours before the procedure.

Antihistamines are frequently used alongside corticosteroids. H1-receptor antagonists block the effects of histamine at peripheral receptors, helping to reduce symptoms such as urticaria, pruritus, and rhinorrhoea. Non-sedating agents such as cetirizine 10 mg or loratadine 10 mg are generally preferred for oral pre-medication; chlorphenamine (also known as chlorpheniramine) may be used intramuscularly or intravenously in the acute setting but causes significant sedation and is not recommended at 10 mg orally for routine pre-medication. Some centres also incorporate an H2-receptor antagonist (e.g., famotidine) to provide broader histamine blockade, though evidence for additional benefit remains limited; ranitidine is no longer available in the UK following its withdrawal by the MHRA.

For the acute treatment of severe contrast reactions, the following agents are used:

• Adrenaline (epinephrine) — the first-line treatment for anaphylaxis, administered intramuscularly at 0.5 mg of 1 mg/mL (1:1000) solution into the anterolateral thigh in adults, as per Resuscitation Council UK (RCUK) guidelines. This may be repeated every 5 minutes if there is no improvement. Antihistamines and corticosteroids must not delay the administration of adrenaline.

• Hydrocortisone IV — may be considered as an adjunct in refractory reactions or where concomitant asthma or persistent shock is present, but is not recommended routinely to prevent biphasic reactions per current RCUK guidance.

• Salbutamol — a short-acting beta-2 agonist used via nebuliser for bronchospasm that does not respond to adrenaline alone.

• IV fluids — administered for hypotension and cardiovascular compromise.

• IV glucagon — may be considered by specialists in cases of refractory anaphylaxis in patients taking beta-blockers, as beta-blockade can impair the response to adrenaline.

Antihistamines are adjuncts for cutaneous symptoms (e.g., urticaria, pruritus) only and do not treat airway, breathing, or circulatory compromise. All medications should be used under clinical supervision, and dosing should follow current BNF, MHRA, and Resuscitation Council UK guidance.

Relevant guidance: Resuscitation Council UK — Emergency treatment of anaphylaxis (2021, updated); BNF; ESUR Guidelines on Contrast Agents.

NHS Pre-Medication Protocols Before Contrast Administration

NHS pre-medication typically involves prednisolone 30–50 mg orally at 12 and 2 hours before contrast, plus a non-sedating antihistamine one hour prior, following RCR and ESUR guidance.

Within the NHS, pre-medication protocols for patients with a history of contrast reactions are not universally standardised across all trusts, but most follow guidance informed by the Royal College of Radiologists (RCR) and the European Society of Urogenital Radiology (ESUR). These protocols are designed to reduce the risk of a repeat reaction in patients who have previously experienced a moderate or severe immediate response to contrast media.

A commonly used NHS pre-medication regimen for patients at elevated risk includes:

• Prednisolone 30–50 mg orally — administered at approximately 12 hours and 2 hours before contrast injection.

• A non-sedating H1 antihistamine (e.g., cetirizine 10 mg or loratadine 10 mg orally) — given approximately 1 hour before the procedure. If a sedating antihistamine such as chlorphenamine is used in this setting, the oral adult dose is 4 mg, and patients should be counselled about sedation and advised not to drive.

• Some centres also add an H2 antihistamine (e.g., famotidine), though evidence for additional benefit remains limited.

Patients should always follow the specific regimen prescribed by their clinical team, as local Trust protocols may vary. The BNF and local pharmacy teams can advise on appropriate dosing.

It is important to understand that pre-medication reduces but does not eliminate the risk of a breakthrough reaction. Patients who have received pre-medication and those at higher risk should remain under observation following contrast administration, in line with local departmental policy. The imaging department should have resuscitation equipment and trained personnel readily available at all times.

In cases where the procedure is urgent and there is insufficient time for a full oral corticosteroid course, an accelerated intravenous protocol using hydrocortisone may be employed; however, this is considered less effective than the standard oral regimen, and the clinical necessity of the procedure must be carefully weighed against the patient's individual risk profile.

Patients should always inform their GP, radiologist, or referring clinician of any previous contrast reactions before attending for an imaging appointment. This allows adequate time for pre-medication to be prescribed and for the radiology team to prepare appropriately. Patients with known severe reactions may require specialist allergy review prior to any future contrast exposure.

Relevant guidance: RCR standards on intravascular contrast agent administration; ESUR Guidelines on Contrast Agents (latest version); BNF.

Managing Acute Allergic Reactions to Contrast Media

Severe contrast reactions require immediate adrenaline 0.5 mg IM, high-flow oxygen, and IV fluids; observation should last at least 6 hours if more than one adrenaline dose was needed.

Despite pre-medication and the use of modern low-osmolar contrast agents, acute reactions can still occur and must be managed promptly. Radiology departments across the NHS are required to have clear protocols and trained staff capable of recognising and treating contrast reactions at all severity levels.

Mild reactions — such as limited urticaria, mild nausea, or a sensation of warmth — are often self-limiting and may not require pharmacological intervention beyond close observation. Chlorphenamine 10 mg IM (or an appropriate oral antihistamine) may be administered to relieve itching and urticaria.

Not sure if this is normal? Chat with one of our pharmacists →

Moderate reactions — including widespread urticaria, facial oedema, mild bronchospasm, or vomiting — typically warrant active treatment:

• Chlorphenamine 10 mg IM or IV for cutaneous symptoms

• Salbutamol nebuliser for bronchospasm

• Continuous monitoring of vital signs

• Escalation to emergency management if the patient's condition deteriorates

Severe reactions (anaphylaxis) require immediate emergency management in line with Resuscitation Council UK guidelines. Antihistamines and corticosteroids must not delay the administration of adrenaline:

1. Call for emergency assistance immediately.
2. Administer adrenaline 0.5 mg IM of 1 mg/mL (1:1000) into the anterolateral thigh — repeat every 5 minutes if there is no improvement.
3. Lay the patient flat with legs elevated (unless breathing is compromised, in which case allow the patient to sit up).
4. Administer high-flow oxygen.
5. Establish IV access and administer IV fluids for hypotension.
6. Chlorphenamine 10 mg IV and hydrocortisone IV may be given as adjuncts — hydrocortisone is reserved for refractory reactions or where concomitant asthma or persistent shock is present, and is not routinely recommended to prevent biphasic reactions.
7. In patients taking beta-blockers with refractory anaphylaxis, IV glucagon may be considered in a specialist setting.
8. Transfer to emergency care for ongoing monitoring.

Following resolution of anaphylaxis, the duration of observation should be risk-stratified according to clinical presentation:

• At least 2 hours for patients with a mild-to-moderate reaction who have recovered fully after a single dose of adrenaline and have no high-risk features.

• At least 6 hours for patients who required more than one dose of adrenaline or have other concerning features.

• At least 12 hours (or overnight) for patients with severe or protracted reactions, or those with high-risk features such as severe asthma.

All reactions should be documented thoroughly. Suspected adverse reactions to contrast media should be reported via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk), particularly if a novel or unexpected reaction pattern is observed. Patients should be referred for specialist allergy assessment following a significant reaction, in line with NICE CG134.

Relevant guidance: Resuscitation Council UK — Emergency treatment of anaphylaxis (2021, updated); NICE CG134: Anaphylaxis — assessment and referral after emergency treatment; ESUR Guidelines on Contrast Agents.

Who Is at Higher Risk and When to Seek Medical Advice

A previous moderate or severe contrast reaction is the strongest risk factor; patients on beta-blockers, those with atopic conditions, and those with known drug allergies are also at elevated risk.

Certain patient groups are at significantly higher risk of experiencing an adverse reaction to contrast media. Identifying these individuals before the procedure allows clinicians to implement appropriate precautions, including pre-medication, alternative imaging modalities, or specialist referral.

Key risk factors include:

• Previous contrast reaction — the single strongest predictor; patients with a prior moderate or severe immediate reaction have a substantially elevated risk of recurrence.

• Atopic conditions — including asthma, eczema, and allergic rhinitis; these patients have a heightened baseline immune reactivity.

• Known drug allergies — particularly to multiple agents, suggesting a broadly reactive immune system.

• Renal impairment — whilst not directly linked to allergic reactions, reduced renal function increases the risk of post-contrast acute kidney injury (PC-AKI), a separate but important concern. Patients with severe chronic kidney disease (CKD) should also be aware that, whilst modern macrocyclic gadolinium-based agents carry a very low risk, severe renal impairment was historically associated with nephrogenic systemic fibrosis (NSF) with older gadolinium agents; current ESUR guidance provides specific recommendations for this group.

• Cardiac conditions — patients with significant cardiovascular disease may tolerate haemodynamic changes associated with reactions less well.

• Beta-blocker use — these medications can blunt the response to adrenaline, making anaphylaxis more difficult to treat and potentially more severe.

• ACE inhibitor use — some evidence suggests ACE inhibitors may be associated with more severe reactions in certain patients, though the evidence is limited and inconsistent; decisions regarding their use around contrast procedures should be individualised in discussion with the clinical team.

There is no established link between seafood or shellfish allergy and an increased risk of iodinated contrast reactions, despite this being a widely held misconception. Current RCR and ESUR guidance does not support routine pre-medication based on shellfish allergy alone.

Patients should seek medical advice if:

• They have experienced any previous reaction to contrast media, however mild.

• They have a history of severe allergic reactions (anaphylaxis) to any substance.

• They are taking beta-blockers or ACE inhibitors, so that the clinical team can assess their individual risk.

• They develop any new or unexpected symptoms following a contrast procedure, including rash, swelling, breathlessness, or dizziness.

If symptoms develop after leaving the imaging department, patients should contact their GP urgently or call 999 if symptoms are severe. Early communication between patients, GPs, and radiology teams remains the most effective safeguard against preventable harm. Suspected adverse reactions to contrast media can also be reported directly by patients via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Relevant guidance: ESUR Guidelines on Contrast Agents (iodinated and gadolinium sections); RCR standards on intravascular contrast agent administration; NHS information on anaphylaxis and imaging with contrast.

Frequently Asked Questions